{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+Methylprednisolone", "query": { "intervention": "Intravenous Methylprednisolone" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 147, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravenous+Methylprednisolone&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T07:33:01.773Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02176031", "title": "Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease" ], "interventions": [ { "name": "Natalizumab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2015-01", "completion_date": "2019-02", "has_results": true, "last_update_posted_date": "2020-04-17", "last_synced_at": "2026-09-25T07:33:01.773Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02176031" }, { "nct_id": "NCT03407144", "title": "Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone/prednisolone", "type": "DRUG" }, { "name": "bleomycin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "Radiotherapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "3 Years to 25 Years" }, "enrollment_count": 340, "start_date": "2018-04-09", "completion_date": "2026-11-06", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-25T07:33:01.773Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03407144" }, { "nct_id": "NCT00230035", "title": "Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)", "type": "PROCEDURE" }, { "name": "Autologous CD34+HPC transplantation (HSCT)", "type": "PROCEDURE" }, { "name": "Plasmapheresis", "type": "PROCEDURE" }, { "name": "Rabbit anti-thymocyte globulin", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Growth colony stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Intravenous immunoglobulin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 0, "start_date": "2005-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-09-25T07:33:01.773Z", "location_count": 5, "location_summary": "La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Manhassat", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00230035" }, { "nct_id": "NCT05201469", "title": "VIBRANT: VIB4920 for Active Lupus Nephritis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "VIB4920", "type": "DRUG" }, { "name": "Placebo for VIB4920", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2022-12-15", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-25T07:33:01.773Z", "location_count": 17, "location_summary": "La Jolla, California • Los Angeles, California • Orange, California + 13 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05201469" }, { "nct_id": "NCT02626455", "title": "Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Copanlisib (BAY80-6946)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 551, "start_date": "2016-01-06", "completion_date": "2023-11-10", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-09-25T07:33:01.773Z", "location_count": 10, "location_summary": "Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "West Covina", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Thomasville", "state": "Georgia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02626455" }, { "nct_id": "NCT01985126", "title": "An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab 16 mg/kg (Part 1)", "type": "DRUG" }, { "name": "Daratumumab 8 mg/kg (Part 1)", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Daratumumab (Part 2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2013-09-27", "completion_date": "2017-05-30", "has_results": true, "last_update_posted_date": "2018-06-25", "last_synced_at": "2026-09-25T07:33:01.773Z", "location_count": 15, "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01985126" }, { "nct_id": "NCT01436305", "title": "Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation", "Renal Transplantation" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "Basiliximab", "type": "BIOLOGICAL" }, { "name": "Short-term Tac", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "Belatacept", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 19, "start_date": "2011-09", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-09-25T07:33:01.773Z", "location_count": 3, "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01436305" }, { "nct_id": "NCT03994731", "title": "Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Gout" ], "interventions": [ { "name": "Pegloticase", "type": "BIOLOGICAL" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "folic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "gout flare prophylaxis regimen", "type": "DRUG" }, { "name": "fexofenadine", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2019-06-13", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-09-25T07:33:01.773Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03994731" }, { "nct_id": "NCT00076752", "title": "Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Rituxan (rituximab)", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 9, "start_date": "2004-01-30", "completion_date": "2013-10-15", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-25T07:33:01.773Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00076752" }, { "nct_id": "NCT00418145", "title": "Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "megadose oral methylprednisolone", "type": "DRUG" }, { "name": "IV methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Lublin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 16, "start_date": "2003-09", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2017-05-18", "last_synced_at": "2026-09-25T07:33:01.773Z", "location_count": 10, "location_summary": "New Brunswick, New Jersey • Brooklyn, New York • Buffalo, New York + 3 more", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00418145" } ] }